4.6 Review

Cardiovascular actions and therapeutic potential of tanshinone IIA

Journal

ATHEROSCLEROSIS
Volume 220, Issue 1, Pages 3-10

Publisher

ELSEVIER IRELAND LTD
DOI: 10.1016/j.atherosclerosis.2011.06.041

Keywords

Tanshinone IIA; Atherosclerosis; Anti-oxidant; Oxidized LDL; Myocardial infarction; Cardiac hypertrophy

Funding

  1. National Natural Science Foundation of China [30472022]
  2. National Major Project Key New Drug Creation and Manufacturing Program [2011ZX09401-307, 2009ZX09102-152, 2009ZX09303-007]
  3. People's Government of Guangdong Province [2003A30904]
  4. Ministry of Education [104146]
  5. Key Projects in Modernization of Traditional Chinese Medicine in Guangdong Province [2003B31713]
  6. Guangzhou City Scientific Bureau [2003Z1-E5011]
  7. National Health & Medical Research Council of Australia
  8. National Heart Foundation of Australia
  9. Diabetes Australia Research Trust
  10. Ministry of Education of the People's Republic of China

Ask authors/readers for more resources

Tanshinone IIA (TS), a pharmacologically active component isolated from the rhizome of the Chinese herb Salvia miltiorrhiza Bunge (Danshen), has been clinically used in Asian countries for the prevention and treatment of coronary heart disease. Recently, the pharmacological properties of TS in the cardiovascular system have attracted great interest. Emerging experimental studies and clinical trials have demonstrated that TS prevents atherogenesis as well as cardiac injury and hypertrophy. In atherosclerosis, TS acts by inhibiting LDL oxidation, monocyte adhesion to endothelium, smooth muscle cell migration and proliferation, macrophage cholesterol accumulation, proinflammatory cytokine expression and platelet aggregation. TS has some activity and potential to stabilize atherosclerotic plaques. The cardioprotective effects of TS are mainly related to its anti-oxidant and anti-inflammatory actions. In this review, we focus on the protective effects and the mechanism of action of TS in the cardiovascular system, and provide a novel perspective on clinical use of TS. (C) 2011 Elsevier Ireland Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available